{"id":528736,"date":"2021-08-17T07:03:40","date_gmt":"2021-08-17T11:03:40","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/taysha-gene-therapies-to-host-key-opinion-leader-webinar-on-tsha-118-for-the-treatment-of-cln1-disease\/"},"modified":"2021-08-17T07:03:40","modified_gmt":"2021-08-17T11:03:40","slug":"taysha-gene-therapies-to-host-key-opinion-leader-webinar-on-tsha-118-for-the-treatment-of-cln1-disease","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/taysha-gene-therapies-to-host-key-opinion-leader-webinar-on-tsha-118-for-the-treatment-of-cln1-disease\/","title":{"rendered":"Taysha Gene Therapies to Host Key Opinion Leader Webinar on TSHA-118 for the Treatment of CLN1 Disease"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwlistdisc { list-style-type: disc }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Taysha Gene Therapies to Host Key Opinion Leader Webinar on TSHA-118 for the Treatment of CLN1 Disease<\/b><\/p>\n<p class=\"bwalignc\"><i>Virtual event on Monday, August 30, 2021, at 10:00 a.m. ET will provide an overview of CLN1 disease, discuss natural history, the TSHA-118 program and clinical development strategy<\/i><\/p>\n<p>DALLAS&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nTaysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced it will host a virtual key opinion leader (KOL) webinar on TSHA-118 for the treatment of CLN1 disease on Monday, August 30, 2021, from 10:00 a.m. to 12:30 p.m. ET.\n<\/p>\n<p>\nThe event will feature a presentation from key opinion leader Angela Schulz, M.D., Ph.D., University Medical Center Hamburg-Eppendorf, who will provide an overview of CLN1 disease, a severe, neurodegenerative lysosomal storage disease with no approved treatment, and discuss the natural history of the disease.\n<\/p>\n<p>\nTopics of discussion will also include the patient and caregiver perspective on the burden of disease, preclinical pharmacology and toxicology data for TSHA-118, and the clinical development strategy for the TSHA-118 program. A question and answer session will follow each formal presentation.\n<\/p>\n<p>\nThe event will feature presentations from:\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nSharon King, President of Taylor\u2019s Tale, who will discuss the burden of disease and provide a patient and caregiver perspective\n<\/li>\n<li>\nSteven Gray, Ph.D., Associate Professor in the Department of Pediatrics at UT Southwestern and Chief Scientific Advisor at Taysha, who will review the preclinical and pharmacology data for TSHA-118 for the treatment of CLN1 disease\n<\/li>\n<li>\nSuyash Prasad, MBBS, M.Sc., MRCP, MRCPCH, FFPM, CMO and Head of R&amp;D of Taysha, who will discuss the clinical development strategy for TSHA-118\n<\/li>\n<\/ul>\n<p>\nRegistration for this event is available through <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Flifesci.rampard.com%2FWebcastingAppv5%2FEvents%2FRegistration%2Fregistration.jsp%3FY2lk%3DMTM1Nw%3D%3D&amp;esheet=52477772&amp;newsitemid=20210817005281&amp;lan=en-US&amp;anchor=LifeSci+Events&amp;index=1&amp;md5=492a3ab18a64f672dc36bc2ec77a4216\">LifeSci Events<\/a>. A live video webcast will be available in the \u201c<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fir.tayshagtx.com%2Fnews-events%2Fevents-presentations&amp;esheet=52477772&amp;newsitemid=20210817005281&amp;lan=en-US&amp;anchor=Events+%26amp%3B+Media&amp;index=2&amp;md5=2b7f02cc5ae384292b5942a82467b176\">Events &amp; Media<\/a>\u201d section of the Taysha corporate website. An archived version of the event will be available on the website for 60 days.\n<\/p>\n<p><b>About Taysha Gene Therapies <\/b><\/p>\n<p>\nTaysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our team\u2019s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully integrated platform\u2014an engine for potential new cures\u2014with a goal of dramatically improving patients\u2019 lives. More information is available at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.tayshagtx.com&amp;esheet=52477772&amp;newsitemid=20210817005281&amp;lan=en-US&amp;anchor=www.tayshagtx.com&amp;index=3&amp;md5=f4aca8c36637379b2cf9a604752d0588\">www.tayshagtx.com<\/a>.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210817005281r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20210817005281\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20210817005281\/en\/<\/a><\/span><\/p>\n<p><b>Company Contact:<br \/>\n<\/b><br \/>Kimberly Lee, D.O.<br \/>\n<br \/>SVP, Corporate Communications and Investor Relations<br \/>\n<br \/>Taysha Gene Therapies<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:klee@tayshagtx.com\">klee@tayshagtx.com<\/a><\/p>\n<p><b>Media Contact:<br \/>\n<\/b><br \/>Carolyn Hawley<br \/>\n<br \/>Canale Communications<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:carolyn.hawley@canalecomm.com\">carolyn.hawley@canalecomm.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> United States North America Texas<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Health Genetics General Health Clinical Trials Research Science Pharmaceutical<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20210817005281\/en\/899637\/3\/Taysha_Logo.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Taysha Gene Therapies to Host Key Opinion Leader Webinar on TSHA-118 for the Treatment of CLN1 Disease Virtual event on Monday, August 30, 2021, at 10:00 a.m. ET will provide an overview of CLN1 disease, discuss natural history, the TSHA-118 program and clinical development strategy DALLAS&#8211;(BUSINESS WIRE)&#8211; Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced it will host a virtual key opinion leader (KOL) webinar on TSHA-118 for the treatment of CLN1 disease on Monday, August 30, 2021, from 10:00 a.m. to 12:30 p.m. ET. The event &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/taysha-gene-therapies-to-host-key-opinion-leader-webinar-on-tsha-118-for-the-treatment-of-cln1-disease\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Taysha Gene Therapies to Host Key Opinion Leader Webinar on TSHA-118 for the Treatment of CLN1 Disease&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-528736","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Taysha Gene Therapies to Host Key Opinion Leader Webinar on TSHA-118 for the Treatment of CLN1 Disease - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/taysha-gene-therapies-to-host-key-opinion-leader-webinar-on-tsha-118-for-the-treatment-of-cln1-disease\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Taysha Gene Therapies to Host Key Opinion Leader Webinar on TSHA-118 for the Treatment of CLN1 Disease - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Taysha Gene Therapies to Host Key Opinion Leader Webinar on TSHA-118 for the Treatment of CLN1 Disease Virtual event on Monday, August 30, 2021, at 10:00 a.m. ET will provide an overview of CLN1 disease, discuss natural history, the TSHA-118 program and clinical development strategy DALLAS&#8211;(BUSINESS WIRE)&#8211; Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced it will host a virtual key opinion leader (KOL) webinar on TSHA-118 for the treatment of CLN1 disease on Monday, August 30, 2021, from 10:00 a.m. to 12:30 p.m. ET. The event &hellip; Continue reading &quot;Taysha Gene Therapies to Host Key Opinion Leader Webinar on TSHA-118 for the Treatment of CLN1 Disease&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/taysha-gene-therapies-to-host-key-opinion-leader-webinar-on-tsha-118-for-the-treatment-of-cln1-disease\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-08-17T11:03:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210817005281r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/taysha-gene-therapies-to-host-key-opinion-leader-webinar-on-tsha-118-for-the-treatment-of-cln1-disease\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/taysha-gene-therapies-to-host-key-opinion-leader-webinar-on-tsha-118-for-the-treatment-of-cln1-disease\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Taysha Gene Therapies to Host Key Opinion Leader Webinar on TSHA-118 for the Treatment of CLN1 Disease\",\"datePublished\":\"2021-08-17T11:03:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/taysha-gene-therapies-to-host-key-opinion-leader-webinar-on-tsha-118-for-the-treatment-of-cln1-disease\\\/\"},\"wordCount\":515,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/taysha-gene-therapies-to-host-key-opinion-leader-webinar-on-tsha-118-for-the-treatment-of-cln1-disease\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210817005281r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/taysha-gene-therapies-to-host-key-opinion-leader-webinar-on-tsha-118-for-the-treatment-of-cln1-disease\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/taysha-gene-therapies-to-host-key-opinion-leader-webinar-on-tsha-118-for-the-treatment-of-cln1-disease\\\/\",\"name\":\"Taysha Gene Therapies to Host Key Opinion Leader Webinar on TSHA-118 for the Treatment of CLN1 Disease - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/taysha-gene-therapies-to-host-key-opinion-leader-webinar-on-tsha-118-for-the-treatment-of-cln1-disease\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/taysha-gene-therapies-to-host-key-opinion-leader-webinar-on-tsha-118-for-the-treatment-of-cln1-disease\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210817005281r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2021-08-17T11:03:40+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/taysha-gene-therapies-to-host-key-opinion-leader-webinar-on-tsha-118-for-the-treatment-of-cln1-disease\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/taysha-gene-therapies-to-host-key-opinion-leader-webinar-on-tsha-118-for-the-treatment-of-cln1-disease\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/taysha-gene-therapies-to-host-key-opinion-leader-webinar-on-tsha-118-for-the-treatment-of-cln1-disease\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210817005281r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210817005281r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/taysha-gene-therapies-to-host-key-opinion-leader-webinar-on-tsha-118-for-the-treatment-of-cln1-disease\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Taysha Gene Therapies to Host Key Opinion Leader Webinar on TSHA-118 for the Treatment of CLN1 Disease\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Taysha Gene Therapies to Host Key Opinion Leader Webinar on TSHA-118 for the Treatment of CLN1 Disease - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/taysha-gene-therapies-to-host-key-opinion-leader-webinar-on-tsha-118-for-the-treatment-of-cln1-disease\/","og_locale":"en_US","og_type":"article","og_title":"Taysha Gene Therapies to Host Key Opinion Leader Webinar on TSHA-118 for the Treatment of CLN1 Disease - Market Newsdesk","og_description":"Taysha Gene Therapies to Host Key Opinion Leader Webinar on TSHA-118 for the Treatment of CLN1 Disease Virtual event on Monday, August 30, 2021, at 10:00 a.m. ET will provide an overview of CLN1 disease, discuss natural history, the TSHA-118 program and clinical development strategy DALLAS&#8211;(BUSINESS WIRE)&#8211; Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced it will host a virtual key opinion leader (KOL) webinar on TSHA-118 for the treatment of CLN1 disease on Monday, August 30, 2021, from 10:00 a.m. to 12:30 p.m. ET. The event &hellip; Continue reading \"Taysha Gene Therapies to Host Key Opinion Leader Webinar on TSHA-118 for the Treatment of CLN1 Disease\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/taysha-gene-therapies-to-host-key-opinion-leader-webinar-on-tsha-118-for-the-treatment-of-cln1-disease\/","og_site_name":"Market Newsdesk","article_published_time":"2021-08-17T11:03:40+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210817005281r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/taysha-gene-therapies-to-host-key-opinion-leader-webinar-on-tsha-118-for-the-treatment-of-cln1-disease\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/taysha-gene-therapies-to-host-key-opinion-leader-webinar-on-tsha-118-for-the-treatment-of-cln1-disease\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Taysha Gene Therapies to Host Key Opinion Leader Webinar on TSHA-118 for the Treatment of CLN1 Disease","datePublished":"2021-08-17T11:03:40+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/taysha-gene-therapies-to-host-key-opinion-leader-webinar-on-tsha-118-for-the-treatment-of-cln1-disease\/"},"wordCount":515,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/taysha-gene-therapies-to-host-key-opinion-leader-webinar-on-tsha-118-for-the-treatment-of-cln1-disease\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210817005281r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/taysha-gene-therapies-to-host-key-opinion-leader-webinar-on-tsha-118-for-the-treatment-of-cln1-disease\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/taysha-gene-therapies-to-host-key-opinion-leader-webinar-on-tsha-118-for-the-treatment-of-cln1-disease\/","name":"Taysha Gene Therapies to Host Key Opinion Leader Webinar on TSHA-118 for the Treatment of CLN1 Disease - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/taysha-gene-therapies-to-host-key-opinion-leader-webinar-on-tsha-118-for-the-treatment-of-cln1-disease\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/taysha-gene-therapies-to-host-key-opinion-leader-webinar-on-tsha-118-for-the-treatment-of-cln1-disease\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210817005281r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2021-08-17T11:03:40+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/taysha-gene-therapies-to-host-key-opinion-leader-webinar-on-tsha-118-for-the-treatment-of-cln1-disease\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/taysha-gene-therapies-to-host-key-opinion-leader-webinar-on-tsha-118-for-the-treatment-of-cln1-disease\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/taysha-gene-therapies-to-host-key-opinion-leader-webinar-on-tsha-118-for-the-treatment-of-cln1-disease\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210817005281r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210817005281r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/taysha-gene-therapies-to-host-key-opinion-leader-webinar-on-tsha-118-for-the-treatment-of-cln1-disease\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Taysha Gene Therapies to Host Key Opinion Leader Webinar on TSHA-118 for the Treatment of CLN1 Disease"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/528736","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=528736"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/528736\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=528736"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=528736"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=528736"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}